Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02364128 · ClinicalTrials.gov registry record · Phase 2
Improving Patient Decisions About Bariatric Surgery
A Phase 2 study, sponsored by University of Michigan.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,000
- Enrollment target
NCT02364128: Completed Phase 2 study, sponsored by University of Michigan.
NCT02364128 is a Phase 2 study that has completed, run by University of Michigan. The registered enrollment target is 1,000 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (652% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02364128, a Phase 2 study, has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,000 participants
- Enrollment target
Study Summary
At least 15 million Americans are morbidly obese, or more than 100 pounds overweight. Medical treatments including drugs and behavior modification have proven ineffective in producing significant and lasting weight loss in this group. While bariatric surgery is extremely effective for most patients, it also carries risks for both short and long-term complications. There are currently four different types of bariatric surgery available and the risks and benefits of these procedures vary widely and are strongly affected by patient and clinical characteristics. Decision making under these circumstances should reflect informed patient's values and preferences regarding these trade-offs. Instead, the choice of bariatric procedure is more often driven by the beliefs and experiences of the bariatric surgeon that a patient happens to see. Variability in the type of surgery recommended to patients likely results from some combination of surgeons' subjective opinions and personal experiences with regard to the risks and benefits of the treatment options and delegated decision making on the part of patients. The goals of this research proposal are to develop, implement, and evaluate an informed decision support tool for treatment of morbid obesity. This project will be conducted within the context of the Michigan Bariatric Surgery Collaborative (MBSC), which is a statewide clinical registry and quality improvement program that has the participation of virtually every bariatric surgeon and program in the state of Michigan. The MBSC registry now includes externally audited clinical data for more than 80,000 consecutive bariatric surgery patients. MBSC outcome measures include complications occurring within 30 days as well as weight loss, comorbidity resolution, quality of life and satisfaction at 1, 2, and 3 years after bariatric surgery.
Primary Outcome
Decisional measures
Interventions
- BEHAVIORAL Decider Guider: Weight Loss
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2014-01-01 |
| Est. Completion | 2018-09-15 |
| Phase | Phase 2 |
What the finished NCT02364128 record still lists
NCT02364128 is an interventional study that assigns participants to a tested intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (652% higher).
The record links to 0 conditions, and to 1 intervention - of which Decider Guider: Weight Loss is the first listed.
NCT02364128 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02364128 about?
NCT02364128 is a clinical study titled "Improving Patient Decisions About Bariatric Surgery". At least 15 million Americans are morbidly obese, or more than 100 pounds overweight. Medical treatments including drugs and behavior modification have proven ineffective in producing significant and lasting weight loss in this group. While bariatric surgery is extremely effective for most patients,...
What is the current status of trial NCT02364128?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,000 participants. The study started on 2014-01-01. Estimated completion is 2018-09-15.
What interventions are being tested in trial NCT02364128?
The interventions under investigation include: Decider Guider: Weight Loss (BEHAVIORAL).
Who is sponsoring clinical trial NCT02364128?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02364128's enrollment target sits among peer trials
1,000 25th of 2000 higher than 1,975 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI